Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts.

During the past decade, Dana Farber Cancer Inst. ; Dept. of Medical Oncology conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 4 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Dana Farber Cancer Inst. ; Dept. of Medical Oncology" are "Bladder Cancer" (2 trials), "Cancer" (1 trials), "Chronic Myelogenous Leukemia" (1 trials), "Classical Hodgkin's Lymphoma" (1 trials) and "Leukemia" (1 trials). Many other conditions were trialed in "Dana Farber Cancer Inst. ; Dept. of Medical Oncology" in a lesser frequency.

Most popular intervention types in "Dana Farber Cancer Inst. ; Dept. of Medical Oncology" are "Drug" (7 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (3 trials), "ABL001" (1 trials), "ABL001 + Nilotinib" (1 trials), "ABL001+dasatinib" (1 trials) and "ABL001+imatinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dana Farber Cancer Inst. ; Dept. of Medical Oncology" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Dana Farber Cancer Inst. ; Dept. of Medical Oncology". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Dana Farber Cancer Inst. ; Dept. of Medical Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dana Farber Cancer Inst. ; Dept. of Medical Oncology, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".